Placenta Accreta Spectrum: In Vitro Fertilization and Non-In Vitro Fertilization and Placenta Accreta Spectrum in a Massachusetts Cohort

Abstract

Objective The incidence of placenta accreta spectrum (PAS) has been increasing in the United States. In addition, there has also been an increase in the utilization of in vitro fertilization (IVF). The IVF pregnancies confer an increased risk of adverse obstetric and neonatal outcomes, but there is limited data on whether IVF is associated with PAS. The aim of this study is to assess the association between IVF and the risk of PAS.

Study Design This was a retrospective cohort study of deliveries from January 1, 2013 to August 1, 2018 at a tertiary hospital in the Massachusetts. IVF pregnancies were compared with non-IVF pregnancies, and PAS diagnosis was confirmed by histopathology reports. Hospital administrative data and medical record review were used, and supplemented with data from birth certificates from the Massachusetts Department of Public Health.

Results We identified 28,344 pregnancies that met inclusion criteria, of which 1,418 (5.0%) were IVF pregnancies. The overall incidence of PAS was 0.4% (2.2% in the IVF group and 0.3% in the non-IVF group). Women who underwent IVF had 5.5 times the risk of PAS (95% confidence interval [CI]: 3.4–8.7) compared with women in the non-IVF group, adjusted for maternal age, nulliparity, and year of delivery ([Table 5]). Compared with women in the non-IVF group, the IVF group had fewer prior cesarean deliveries (22.6 vs. 64.2%) and a lower prevalence of placenta previa (19.4 vs. 44.4%).

Conclusion Women with an IVF pregnancy carry an increased risk of PAS compared with non-IVF. Among women who underwent IVF, there was a lower prevalence of prior cesarean deliveries and placenta previa. Future work is needed to identify the mechanism of association for this increased risk as well as a reliable tool for antenatal detection in this cohort of women.

Key Points

• IVF pregnancies have higher risk of PAS than non-IVF pregnancies.

• IVF pregnancies with PAS do not exhibit common risk factors.

• IVF may be an independent risk factor for PAS.

Keywords

abnormally invasive placenta - abnormal placentation - invasive placentation - placenta accreta spectrum - infertility - in vitro fertilization

Publication History

Received: 06 April 2020

Accepted: 28 May 2020

Article published online:
05 July 2020

• References

• 1 Wu S, Kocherginsky M, Hibbard JU. Abnormal placentation: twenty-year analysis. Am J Obstet Gynecol 2005; 192 (05) 1458-1461
• 2 Creanga AA, Bateman BT, Butwick AJ. et al. Morbidity associated with cesarean delivery in the United States: is placenta accreta an increasingly important contributor?. Am J Obstet Gynecol 2015; 213 (03) 384.e1-384.e11
• 3 Silver RM, Landon MB, Rouse DJ. et al; National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Maternal morbidity associated with multiple repeat cesarean deliveries. Obstet Gynecol 2006; 107 (06) 1226-1232
• 4 Fitzpatrick KE, Sellers S, Spark P, Kurinczuk JJ, Brocklehurst P, Knight M. Incidence and risk factors for placenta accreta/increta/percreta in the UK: a national case-control study. PLoS ONE 2012; 7 (12) e52893
• 5 Miller DA, Chollet JA, Goodwin TM. Clinical risk factors for placenta previa-placenta accreta. Am J Obstet Gynecol 1997; 177 (01) 210-214
• 6 American College of Obstetricians and Gynecologists and Society for the Maternal-Fetal Medicine. Obstetric care consensus no. 7: placenta accreta spectrum. Obstet Gynecol 2018; 132 (06) e259-e275
• 7 Jauniaux E, Dimitrova I, Kenyon N. et al. Impact of placenta previa with placenta accreta spectrum disorder on fetal growth. Ultrasound Obstet Gynecol 2019; 54 (05) 643-649
• 8 Mulla BM, Weatherford R, Redhunt AM. et al. Hemorrhagic morbidity in placenta accreta spectrum with and without placenta previa. Arch Gynecol Obstet 2019; 300 (06) 1601-1606
• 9 Shamshirsaz AA, Erfani H, Shamshirsaz AA. et al. Characteristics and outcomes of placenta accreta spectrum in twins versus singletons: a study from the Pan American Society for Placenta Accreta Spectrum (PAS²). Am J Obstet Gynecol 2020; 222 (06) 624-625
• 10 Philips J, Gurganus M, DeShields S. et al. Prevalence of sonographic markers of placenta accreta spectrum in low-risk pregnancies. Am J Perinatol 2019; 36 (08) 733-780
• 11 Kushnir VA, Barad DH, Albertini DF, Darmon SK, Gleicher N. Systematic review of worldwide trends in assisted reproductive technology 2004-2013. Reprod Biol Endocrinol 2017; 15 (01) 6
• 12 Kaser DJ, Melamed A, Bormann CL. et al. Cryopreserved embryo transfer is an independent risk factor for placenta accreta. Fertil Steril 2015; 103 (05) 1176-84.e2
• 13 Esh-Broder E, Ariel I, Abas-Bashir N, Bdolah Y, Celnikier DH. Placenta accreta is associated with IVF pregnancies: a retrospective chart review. BJOG 2011; 118 (09) 1084-1089
• 14 Modest AM, Johnson KM, Karumanchi SA. et al. Risk of ischemic placental disease is increased following in vitro fertilization with oocyte donation: a retrospective cohort study. J Assist Reprod Genet 2019; 36 (09) 1917-1926
• 15 Dannheim K, Shainker SA, Hecht JL. Hysterectomy for placenta accreta; methods for gross and microscopic pathology examination. Arch Gynecol Obstet 2016; 293 (05) 951-958
• 16 Jauniaux E, Collins S, Burton GJ. Placenta accreta spectrum: pathophysiology and evidence-based anatomy for prenatal ultrasound imaging. Am J Obstet Gynecol 2018; 218 (01) 75-87
• 17 Tantbirojn P, Crum CP, Parast MM. Pathophysiology of placenta creta: the role of decidua and extravillous trophoblast. Placenta 2008; 29 (07) 639-645
• 18 Wright JD, Pri-Paz S, Herzog TJ. et al. Predictors of massive blood loss in women with placenta accreta. Am J Obstet Gynecol 2011; 205 (01) 38.e1-38.e6
• 19 Gibbins KJ, Einerson BD, Varner MW, Silver RM. Placenta previa and maternal hemorrhagic morbidity. J Matern Fetal Neonatal Med 2018; 31 (04) 494-499
• 20 Allen VM, Wilson RD, Cheung A. Genetics Committee; Reproductive Endocrinology and Infertility Committee. Pregnancy outcomes after assisted reproductive technology. J Obstet Gynaecol Can 2006; 28 (03) 220-233
• 21 Imudia AN, Awonuga AO, Kaimal AJ, Wright DL, Styer AK, Toth TL. Elective cryopreservation of all embryos with subsequent cryothaw embryo transfer in patients at risk for ovarian hyperstimulation syndrome reduces the risk of adverse obstetric outcomes: a preliminary study. Fertil Steril 2013; 99 (01) 168-173
• 22 Imudia AN, Awonuga AO, Doyle JO. et al. Peak serum estradiol level during controlled ovarian hyperstimulation is associated with increased risk of small for gestational age and preeclampsia in singleton pregnancies after in vitro fertilization. Fertil Steril 2012; 97 (06) 1374-1379
• 23 Kalra SK, Barnhart KT. In vitro fertilization and adverse childhood outcomes: what we know, where we are going, and how we will get there. A glimpse into what lies behind and beckons ahead. Fertil Steril 2011; 95 (06) 1887-1889
• 24 Deng S, Xu J, Zeng J, Hu L, Wu Y. Ovarian stimulation leads to a severe implantation defect in mice. Reprod Biomed Online 2013; 27 (02) 172-175
• 25 Albrecht ED, Bonagura TW, Burleigh DW, Enders AC, Aberdeen GW, Pepe GJ. Suppression of extravillous trophoblast invasion of uterine spiral arteries by estrogen during early baboon pregnancy. Placenta 2006; 27 (4-5) 483-490
• 26 Bonagura TW, Pepe GJ, Enders AC, Albrecht ED. Suppression of extravillous trophoblast vascular endothelial growth factor expression and uterine spiral artery invasion by estrogen during early baboon pregnancy. Endocrinology 2008; 149 (10) 5078-5087
• 27 Erfani H, Fox KA, Clark SL. et al. Maternal outcomes in unexpected placenta accreta spectrum disorders: single-center experience with a multidisciplinary team. Am J Obstet Gynecol 2019; 221 (04) 337.e1-337.e5
• 28 Shamshirsaz AA, Fox KA, Erfani H. et al. Outcomes of planned compared with urgent deliveries using a multidisciplinary team approach for morbidly adherent placenta. Obstet Gynecol 2018; 131 (02) 234-241
• 29 Luke B, Stern JE, Kotelchuck M, Declercq ER, Cohen B, Diop H. Birth outcomes by infertility diagnosis analyses of the Massachusetts outcomes study of assisted reproductive technologies (MOSART). J Reprod Med 2015; 60 (11-12): 480-490